ACVR2A and nasopharyngeal carcinoma: Here our data shows a 24.3% (17/70 tumors) rate of TGF-β/SMAD pathway gene alteration in NPC, targeting TGFBR2, TGFBR3, ACVR2A, and SMAD4 (Fig. 5A).